Search research articles
Contact Us
Filters
Showing results (61-70 of 103) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
Axel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 14, 2017
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
Tara C Gangadhar, Wen-Jen Hwu, Michael A Postow, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Omid Hamid, Igor Puzanov, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, et al.
The Lancet. Oncology
|
July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B Corcoran, Chloe E Atreya, Gerald S Falchook, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 103) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
Axel Hauschild, Sanjiv S Agarwala, Uwe Trefzer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 14, 2017
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
Tara C Gangadhar, Wen-Jen Hwu, Michael A Postow, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2016
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, et al.
JAMA Oncology
|
July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
Igor Puzanov, Antoni Ribas, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Omid Hamid, Igor Puzanov, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, et al.
The Lancet. Oncology
|
July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 23, 2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B Corcoran, Chloe E Atreya, Gerald S Falchook, et al.
Page
of 11